Granules India tumbles after getting 11 observations from Portuguese drug regulator

Granules India lost 9.93% to Rs 101.10 at 13:34 IST on BSE after Infarmed, the Portuguese drug regulator completed inspection of the company's Gagillapur facility with eleven observations.

The announcement was made after market hours on Friday, 6 January 2017.

Meanwhile, the S&P BSE Sensex was up 3 points or 0.01% at 26,762.23

On the BSE, 10.81 lakh shares were traded on the counter so far as against the average daily volumes of 1.51 lakh shares in the past one quarter. The stock had hit a high of Rs 107.10 and a low of Rs 97.80 so far during the day. The stock had hit a 52-week high of Rs 151.15 on 14 August 2016. The stock had hit a 52-week low of Rs 91.45 on 9 November 2016.

The small-cap company has equity capital of Rs 22.12 crore. Face value per share is Re 1.

Granules India announced that Infarmed, Portugal, had conducted a renewal inspection on the company's facility located at Gagillapur, Telangana. In this respect, the company has received the inspection report from Infarmed with eleven observations. The Gagillapur facility manufactures Pharmaceuticals Formulation Intermediates (PFIs) and Finished Dosages (FDs).

The company has initiated necessary steps to address the observations of the inspection agency and will submit its response with a corrective and preventive action plan within the stipulated time, Granules India said. The company will also be requesting the Infarmed for re-inspection of the Gagillapur facility at the earliest. The company is committed to comply with all the required regulatory requirements and follow the best practices of the industry. The company acknowledges the observations as areas of continuous improvements, it added.

Granules India's consolidated net profit rose 26.5% to Rs 40.82 crore on 3.08% growth in net sales to Rs 363.57 crore in Q2 September 2016 over Q2 September 2015.

Granules India produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients for customers in the regulated and semi-regulated markets.

Powered by Capital Market - Live News